PubMed · 1983 · 63 citations · 0 references
MedicineNuclear MedicinePharmacologyEndocrine Nuclear MedicineRadionuclide TherapyTherapeutic Nuclear MedicinePheochromocytoma ImagingRadioiodine TherapyRadiopharmaceutical DesignRadiopharmaceutical TherapyRadiopharmaceuticalsTumor ImagingIodine-123 Metaiodobenzylguanidine ScintigraphyIodine-131 RadiopharmaceuticalsPheochromocytoma DiagnosisPheochromocytoma PathologyRadiopharmaceutical Uptake
A new radiopharmaceutical, [131I]metaiodobenzylguandine, concentrates in some malignant pheochromocytomas. Five patients were treated with two to four doses of [131I]MIBG (99-197 mCi/dose). Two patients had substantial subjective and objective responses. [131I]MIBG is the first chemically synthesized radiopharmaceutical of complex molecular structure to reduce cancer.